Technologieangebote

The technology allows for direct and indirect detection of cancer tissue. It deals with a pharmaceutical compound consisting of three subdomains: (A) for specific cell surface binding to neoplastic cells, (B) for binding radiometals via a chelator domain for e.g. PET, and (C) harboring a fluorescent dye moiety for optical detection. The combination of PET tracer and optical moiety enables the surgeon to localize the tumor preoperatively via PET/CT and intraoperatively through optical detection.

The present invention discloses an antibody which selectively binds SITR1 dependent on its activation status.

The invention discloses a measles virus based oncolytic tumor therapy. The virus encodes antibodies against CTLA-4 or PD-L1 and has proven effectiveness in a in vivo mouse tumor model.

The antibody recognizes the kinase HIPK2 only when phosphorylated at Thr880 and Ser882 and therefore can be used for predicting kinase activity.

The assembly and maintenance of functional nucleoli is essential for cell viability. DKFZ researchers developed anti-sense oligos that target Alu element-containing RNAs, which are essential for intact nucleoli, for cancer cell specific induction of apoptosis.

Combination therapy of wogonin or rocaglamide together with Bcl-2 inhibitors leads to increased efficacy of ABT-263, even in cancer cells which have acquired resistance to ABT-263, and without affecting proliferation of normal T cells and platelets.